HIGH-GRADE SEROUS OVARIAN CANCER

This early-phase study tests a new investigational drug called azirkitug, alone or combined with other drugs, in adults with advanced solid tumors such as lung, head/neck, colorectal, and breast cancers. The main goals are to check safety, side effects, and how the drug moves thr…

This early-stage study tests a new drug called IDE034 in about 150 adults with advanced solid tumors (like lung, ovarian, or colon cancer) that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink …

This study tests a drug called Rina-S in people with advanced solid tumors that have spread or can't be removed by surgery. The goal is to check safety and see if the drug shrinks tumors. About 764 participants with cancers like ovarian, lung, breast, or endometrial cancer will t…

This study tests two drugs, VS-6766 and defactinib, in people with certain gynecological cancers that have come back. The goal is to see if the combination can shrink tumors and how safe it is. About 55 adults with specific gene mutations (RAS, BRAF, or NF1) will take part.

This study tests whether a cancer-killing virus (Olvi-Vec) given into the abdomen can make platinum-resistant ovarian cancer respond to chemotherapy again. About 186 women whose cancer has not responded to at least three prior treatments will receive either Olvi-Vec plus chemo an…

This study is for people with a first-time diagnosis of high-grade serous ovarian cancer. Researchers will collect blood samples before surgery, after chemotherapy, and during maintenance therapy to look for circulating tumor DNA (ctDNA). The goal is to see if ctDNA can predict h…